Katharine Brock

Has grant

Assistant Professor of Pediatric Oncology; Physician, Pediatric Palliative Care

Emory University
Country flagUnited States

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Katharine Brock is an Assistant Professor of Pediatric Oncology and a Physician specializing in Pediatric Palliative Care at Emory University in the United States. Her research primarily focuses on enhancing healthcare utilization and end-of-life outcomes in pediatric oncology, as evidenced by her recent articles on telehealth interventions and the complexities of palliative care. She has also contributed to the understanding of communication in pediatric radiology and the palliative needs of children with cancer.

Recent Grants

Grant: Close

Development and Pilot of a Telehealth Hospice Transition Intervention for Pediatric and Young Adults with Cancer.

Open Date: 2020-07-01

Close Date: 2023-06-01

Grant: Close

Integrated Pediatric Palliative Oncology Care

Open Date: 2018-07-01

Close Date: 2019-06-01

Grant: Close

Integrated Pediatric Palliative Oncology Care

Open Date: 2017-07-01

Close Date: 2018-06-01

Articles (19)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Background/objectives Radiotherapy is an effective palliative treatment in advanced cancer. Shorter palliative treatment courses are recommended for adults, though pediatric data addressing treatment efficacy and toxicity according to radiation therapy (RT) dose and fractionation are limited. Design/methods Total 213 patients aged 21 years or younger receiving 422 palliative radiotherapy treatment courses from 2003 to 2016 were included. Symptom response and treatment‐associated toxicity were recorded and analyzed in relationship to demographic and treatment variables. Results Common diagnoses included sarcoma (32.5%), neuroblastoma (24.9%), leukemia/lymphoma (14.9%), and central nervous system tumors (10.9%). The most common indication for treatment was pain (46.7%). Patients received a median of 10 fractions, 2.5 Gy dose per fraction, and 21 Gy total dose. Number of RT fractions was five or less in 166 (39.3%), six to 10 fractions in 117 (27.2%), and 10 or more fractions in 139 (32.9%) of courses. Complete or partial pain relief was achieved in 85% (151 of 178 evaluable patients), including 77.8% receiving five or less fractions and 89.6% receiving more than five fractions. Highest toxicity was grade 1 in 159 (38.9%), grade 2 in 26 (6.4%), and grade 3 in two (0.5%) treatments. On multivariable analysis, RT delivered 30 or more days from death (OR 12.13, 95% CI: 2.13–69.2, p = .005) and no adjuvant chemotherapy (OR 0.14, 95% CI: 0.03–0.54, p = .005) were significantly associated with pain response, and five or less fractions were significantly associated with lower toxicity (OR 0.24, 95% CI: 0.06–0.97, p = .045). Conclusions Palliative RT courses of five or less fractions result in high rates of pain control and are associated with low toxicity in pediatric patients with cancer.

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Jonathan Ebelhar

Assistant Professor

Emory University

UNITED STATES
View details

Satheesh Chonat

-

UNITED STATES
View details

Bree R. Eaton

-

UNITED STATES
View details

Angela Feraco

Dana-Farber Cancer Institute

UNITED STATES
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.